This new Medicare program offers obesity drugs for $50 a month. Here's what you need to know
Medicare has launched a new pilot program called Bridge that allows eligible seniors to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month copays, starting this week. This represents a major policy shift as Medicare has historically excluded obesity medications from coverage, and could potentially reach millions of beneficiaries and expand access to drugs that normally cost hundreds of dollars monthly.
Summary
For years, popular weight loss drugs known as GLP-1s have been financially inaccessible to most older Americans on Medicare, with monthly costs reaching hundreds of dollars. This week marks a significant change with the launch of the Bridge program, a temporary Medicare pilot initiative that creates a new pathway for coverage of obesity medications. The program specifically targets patients meeting certain criteria, including those with a BMI over 35 and individuals with obesity-related health conditions. Under this program, eligible Medicare beneficiaries can now access GLP-1 drugs from pharmaceutical companies Novo Nordisk and Eli Lilly with a copay of just $50 per month. This represents a major policy reversal for Medicare, which has traditionally barred coverage of medications prescribed solely for weight loss and obesity treatment. The program could dramatically expand patient access to these medications and help prevent costly health complications associated with obesity. Industry estimates suggest the Bridge program could eventually reach as many as 20 million new patients, representing substantial market expansion for both drug manufacturers. With more than 69 million Americans currently enrolled in Medicare, officials anticipate that several million beneficiaries will join the Bridge program immediately upon launch. However, the rollout presents operational challenges. The process requires physicians to submit prior authorization requests to verify that patients meet eligibility requirements before coverage is approved. Healthcare providers have expressed concerns that the influx of new patients could strain already busy clinics and pharmacies, with some doctors cautioning that the healthcare system will need patience during the initial rollout period as patients eagerly begin these medications.
Key Insights
- Medicare has historically barred coverage of medications prescribed solely for obesity, but the new Bridge program creates a temporary pathway that breaks this traditional policy restriction
- GLP-1 obesity drugs from Novo Nordisk and Eli Lilly normally cost hundreds of dollars per month, but the Bridge program reduces the copay to $50 monthly for eligible patients
- Novo Nordisk and Eli Lilly estimate the Bridge program could reach as many as 20 million new patients, representing a major market expansion opportunity
- Physicians must submit prior authorization requests to confirm beneficiary eligibility before coverage approval, adding an administrative step to the enrollment process
- Physicians anticipate that the wave of new patients entering the program could create strain on already busy clinics and pharmacies over the coming months
Topics
Transcript
[0:00] Popular weight loss drugs have remained out of reach for most older Americans in Medicare for years. That's because GLP-1s can cost hundreds of dollars per month, but that changes this week. Starting Wednesday, millions of eligible Medicare patients can access GLP-1 obesity drugs from [music] Novo Nordisk and Eli Lilly for a copay of just $50 per month. It's a major shift for a federal program that has traditionally barred coverage of medications prescribed solely for obesity. So, what happened? Well, there's a new Medicare pilot program called Bridge that's creating a temporary pathway for [0:30] coverage. Patients who meet certain requirements, including those with a BMI of over 35 and people with certain obesity-related conditions, [music] may…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
Inside the rise and fall of Kohl's
Kohl's, once a beloved department store chain, experienced a dramatic decline from its 2018 peak of $82 per share to under $20, losing 70% of its value over five years. New CEO Michael Bender attributes the decline to the company losing its identity and core customer focus, and is now implementing a turnaround strategy centered on returning to the company's original value-oriented approach.
How an ICE contract could boost a stock Trump purchased
President Trump purchased up to $5 million in shares of Axon Enterprise, a Taser manufacturer, in early 2026. Exactly two weeks later, ICE announced a $220 million contract request to quadruple its Taser inventory, prompting questions about potential conflicts of interest, though the White House maintains Trump's trades are managed independently and no contract has yet been awarded.
Why Toyota, Honda And Hyundai Dominate The U.S. Hybrid Car Market
Toyota, Honda, and Hyundai dominate the U.S. hybrid market as hybrid vehicles surge to 15.4% of total sales in 2026, outpacing EV adoption. Toyota's 30-year commitment to hybrid technology has made it the market leader with over 1 million sales, while competitors like GM and Ford are slow to develop robust hybrid lineups, relying on suppliers or pivoting strategy.
Why South Asian music is growing in popularity in the U.S.
South Asian music is experiencing growing popularity in the U.S., with major label Warner Music Group investing in the genre through a new imprint called 5A Junction. Created by music industry strategist Anjula Acharia, the label aims to develop South Asian talent while helping artists blend their cultural identity with global appeal.
Helios Is AMD’s First AI System To Rival Nvidia Vera Rubin — We Got An Exclusive, First Look
AMD has unveiled Helios, its first rack-scale AI system designed to compete with Nvidia's dominant position in AI infrastructure. With major commitments from Meta, Microsoft, OpenAI, and Oracle, Helios aims to capture market share by offering superior efficiency, customizable configurations, and open-source software alternatives to Nvidia's proprietary CUDA ecosystem.